Biocon Limited (BIOCON) AI Stock Analysis

• Market Cap: ₹594.86B
• Dividend Yield: 0.12%
• Average Volume (3M): 208.50K
• Price to Earnings (P/E): 91.6
• Beta (1Y): 1.12
• Revenue Growth: 10.62%
• EPS Growth: -66.88%
• Country: IN
• Employees: 16,315
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.95
• Shares Outstanding: 1,620,907,700
• 10 Day Avg. Volume: 177,351
• 30 Day Avg. Volume: 208,504
• PEG Ratio: -38.08
• Price to Book (P/B): 1.88
• Price to Sales (P/S): 2.66
• P/FCF Ratio: 23.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹437.00
• Price Target Upside: 19.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 4.32
• Revenue Forecast (FY): ₹171.05B

• Rating: 63 Neutral
• Price Target: ₹391.00 ▲(7.36% Upside)
• Action: Reiterated Date: 11/13/25
• Date: Action: Reiterated 11/13/25

Biocon Limited's strong financial performance is the most significant factor contributing to its overall score, reflecting robust revenue growth and profitability. However, the technical analysis suggests caution due to overbought signals, and the high P/E ratio indicates potential overvaluation, which negatively impacts the overall score.

Positive Factors

Revenue Growth

Sustained ~14% revenue growth indicates durable market traction across Biocon's businesses. Over 2–6 months this trend supports reinvestment in R&D and commercialization, strengthens bargaining with partners, and underpins scalability of manufacturing operations and long-term cash generation.

Cash Generation / Free Cash Flow

Improving operating cash flow and positive free cash flow provide the company lasting financial flexibility. This enables funding of capex, biologics scale-up and R&D without heavy reliance on external financing, supporting sustained investment in pipelines and manufacturing capacity.

Diversified Biopharma Business Model

A multi-pronged model (biosimilars, complex generics, CDMO services, licensing) reduces dependence on any single product or market. Structural diversification and manufacturing scale create durable revenue engines and partnership opportunities that mitigate regulatory/product cycle risks over the medium term.

Negative Factors

Declining EPS

A near 28% drop in EPS signals meaningful pressure on per‑share profitability. If driven by structural cost increases, pricing pressure, or nonrecurring items, sustained EPS declines can reduce internal funding capacity for R&D and capex and constrain strategic flexibility over the next several quarters.

Rising Debt Concerns

Although leverage remains reasonable, growing total debt raises interest and refinancing exposure. Higher debt can limit ability to fund organic growth or acquisitions, increase fixed charges, and amplify downside in stressed scenarios, reducing balance sheet optionality over the medium term.

Compressing EBIT Margin

A falling EBIT margin suggests operational cost pressures or pricing erosion, which is critical in competitive biosimilars and generics markets. If margin compression persists, it will weaken profitability resilience and limit the company's capacity to absorb pricing competition or fund long‑cycle biologics investments.

Biocon Limited Business Overview & Revenue Model

Company Description

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

How the Company Makes Money

Biocon makes money primarily by selling pharmaceutical products and related services across a few major revenue streams. (1) Biosimilars and biologics: A significant portion of earnings comes from developing and manufacturing biosimilar versions of biologic drugs and selling them in various markets, either directly where it has commercial presence or through commercialization partners that market and distribute the products; revenues include product sales and, where applicable, milestone payments and profit-sharing/transfer pricing tied to supply agreements. (2) Generics and complex formulations: The company earns revenue from sales of branded and unbranded formulations and active pharmaceutical ingredients (APIs), including complex generics, through both domestic sales and exports; income is driven by volumes, pricing, and regulatory approvals enabling market entry. (3) Contract development and manufacturing (CDMO/CRAMS) and research services: Biocon also generates revenue by providing development, manufacturing, and related services to other pharmaceutical and biotech companies, leveraging its fermentation, biologics, and formulation capabilities; these contracts typically produce service fees and long-term manufacturing income. (4) Licensing/alliances: The company can earn upfront payments, development and regulatory milestones, and royalties or other consideration when it out-licenses assets or co-develops products with partners, particularly for global commercialization of biosimilars/biologics. Key factors that influence earnings include success in R&D and clinical development, regulatory approvals in target markets, manufacturing scale and cost efficiency, product pricing and competition (especially in biosimilars and generics), and the terms and performance of commercialization and supply partnerships.

Biocon Limited Financial Statement Overview

Summary

Biocon Limited exhibits strong financial health with consistent revenue growth and profitability. The company's balance sheet is robust, with a solid equity base and manageable leverage. Cash flow generation is positive, supporting its operational needs. While there are minimal risks associated with rising debt levels, the overall financial outlook remains positive.

Income Statement

Biocon Limited has demonstrated strong revenue growth, with an increase in total revenue from 2024 to 2025. The gross profit margin is robust, reflecting efficient cost management, and the net profit margin is solid, indicating profitability. However, the EBIT margin has decreased compared to the previous year, suggesting potential operational challenges.

Balance Sheet

The company maintains a healthy equity ratio, signifying a strong capital structure with substantial stockholders' equity. The debt-to-equity ratio is reasonable, indicating balanced leverage, but the increase in total debt could pose future risks. The return on equity remains strong, reflecting effective use of equity capital.

Cash Flow

Biocon's operating cash flow has increased, underscoring improved cash generation from operations. The free cash flow is positive, indicating the company can fund its operations and investments, although the growth rate has slowed. The operating cash flow to net income ratio is favorable, showcasing efficient cash conversion.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	164.43B	152.62B	147.56B	111.74B	81.84B	71.43B
Gross Profit	98.38B	92.44B	91.73B	69.62B	50.11B	48.99B
EBITDA	34.13B	31.24B	32.71B	26.57B	19.56B	16.52B
Net Income	4.86B	10.13B	10.22B	4.63B	6.48B	7.41B
Balance Sheet
Total Assets	627.60B	587.97B	560.71B	520.43B	203.94B	185.22B
Cash, Cash Equivalents and Short-Term Investments	64.69B	49.24B	25.74B	37.26B	29.65B	32.24B
Total Debt	165.35B	183.62B	162.77B	180.19B	51.47B	44.81B
Total Liabilities	297.05B	310.85B	307.96B	295.54B	109.24B	100.15B
Stockholders Equity	268.04B	216.44B	197.84B	178.67B	84.33B	76.27B
Cash Flow
Free Cash Flow	-575.00M	17.18B	10.22B	1.26B	-7.48B	-5.87B
Operating Cash Flow	8.03B	40.61B	29.54B	18.52B	11.77B	11.60B
Investing Cash Flow	-12.76B	-2.34B	-10.04B	-142.82B	-16.99B	-36.25B
Financing Cash Flow	14.03B	-18.54B	-23.33B	130.49B	2.42B	25.64B

Biocon Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 364.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOCON, the sentiment is Negative. The current price of 364.2 is below the 20-day moving average (MA) of 385.57, below the 50-day MA of 378.23, and below the 200-day MA of 373.59, indicating a bearish trend. The MACD of -1.71 indicates Positive momentum. The RSI at 40.60 is Neutral, neither overbought nor oversold. The STOCH value of 16.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BIOCON.

Biocon Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CONCORDBIO	66 Neutral	₹108.15B	54.58	―	0.80%	3.63%	-1.21%
BLUEJET	65 Neutral	₹59.16B	57.24	―	0.22%	63.34%	109.89%
BIOCON	63 Neutral	₹594.86B	91.56	―	0.12%	10.62%	-66.88%
JUBLINGREA	61 Neutral	₹89.91B	59.25	―	0.74%	3.80%	64.94%
SYNGENE	61 Neutral	₹160.39B	439.86	―	0.19%	8.57%	-2.93%
PPLPHARMA	55 Neutral	₹176.86B	-41.77	―	0.08%	2.66%	-153.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Biocon Limited Corporate Events

Biocon to Join JP Morgan India Credit Investor Trip in Virtual Meeting

Biocon Limited has informed the stock exchanges that its management will participate in JP Morgan’s annual flagship India Credit Investor Trip on March 11, 2026, via a virtual group interaction. The company emphasized that no unpublished price-sensitive information will be shared during this analyst and institutional investor engagement, underscoring its adherence to regulatory norms and transparent communication practices.

The disclosed meeting schedule signals Biocon’s ongoing efforts to maintain active dialogue with the institutional investor community. Such interactions can influence investor perception and support market understanding of the company’s credit profile and strategic direction, although no immediate operational or financial changes were announced in connection with this event.

Biocon bolsters pharma subsidiaries with fresh preference share funding

Biocon has injected fresh capital into its wholly owned subsidiaries Biocon Biosphere and Biocon Pharma by acquiring large tranches of optionally convertible redeemable non-cumulative preference shares in each entity. The funding is aimed at meeting working capital, capex and general corporate needs, reinforcing the operational and financial support structure within the group while maintaining arm’s-length terms despite the related-party status.

The move signals Biocon’s intent to strengthen its pharmaceutical subsidiaries’ balance sheets and sustain growth in their respective businesses, with Biocon Pharma already a significantly larger revenue contributor than Biocon Biosphere. By channeling funds through preference shares, the parent retains flexibility on future conversion while ensuring that key units have sufficient resources to pursue ongoing projects and expansion plans.

Biocon Publishes Investor Presentation Ahead of Analyst Meets

Biocon Limited has notified stock exchanges that it has prepared an investor presentation for meetings with analysts and institutional investors scheduled on February 25 and 26, 2026. The materials, shared under regulatory disclosure norms, will also be available on the company’s website, signaling ongoing engagement with the financial community and transparency around its business performance and outlook.

The filing, made under India’s listing obligations framework, indicates Biocon’s intent to keep market participants updated ahead of or around key interactions with large investors. While the content of the investor deck is not disclosed in the notice, such presentations typically provide operational and strategic updates that can shape investor perception and influence trading in the company’s shares.

Biocon Raises Rs 4,150 Crore via QIP to Fully Acquire Biocon Biologics

Biocon Limited has raised Rs 4,150 crore (approximately USD 460 million) via a Qualified Institutions Placement, issuing over 112.6 million equity shares at Rs 368.35 each to a broad base of domestic and international institutional investors, including major mutual funds and insurance companies, underscoring strong market confidence in its business model and growth prospects. The company will use the proceeds primarily to finance the buyout of Mylan Inc.’s (Viatris) remaining stake and other minority holdings in Biocon Biologics, repay related acquisition debt and CCD-linked borrowings, and for general corporate purposes, paving the way for Biocon Biologics to become a wholly owned subsidiary by March 31, 2026 and strengthening Biocon’s strategic push in diabetes, oncology and immunology through an integrated biosimilars and generics platform.

Biocon Raises ₹41.5 Billion via Qualified Institutions Placement, Expands Equity Base

Biocon Limited has raised approximately ₹41,500 million through a Qualified Institutions Placement (QIP), issuing 112,664,585 new equity shares of face value ₹5 each at an issue price of ₹368.35 per share to eligible qualified institutional buyers. The capital raise increases Biocon’s paid-up equity share capital from ₹7,54,12,15,940 to ₹8,10,45,38,865, expanding its total equity shares outstanding from 150,82,43,188 to 162,09,07,773, and is expected to strengthen the company’s balance sheet and financial flexibility, with details of major allottees and an updated shareholding pattern to follow in line with SEBI disclosure norms.

Biocon Raises ₹41.5 Billion via QIP, Expands Equity Base

Biocon Limited has raised approximately ₹41,500 million through a qualified institutions placement (QIP) of 11,26,64,585 equity shares at an issue price of ₹368.35 per share, including a premium of ₹363.35. The fundraising, approved by the company’s Fund Raising Committee and completed between January 12 and 14, 2026, increases Biocon’s paid-up equity share capital from ₹7,54,12,15,940 to ₹8,10,45,38,865, expanding its total number of shares from 1,50,82,43,188 to 1,62,09,07,773 and potentially strengthening its balance sheet and financial flexibility for future strategic and operational needs.

Biocon Closes QIP, Raises Capital Through Discounted Share Allocation

Biocon Limited has closed its Qualified Institutions Placement (QIP) of equity shares, initiated on January 12, 2026, after receiving applications and funds from eligible qualified institutional buyers. The company’s Fund Raising Committee approved the closure of the issue on January 14, 2026, and allocated 112,664,585 equity shares at an issue price of ₹368.35 per share, representing a 5% discount to the floor price of ₹387.74, and finalized allocation confirmations to participating investors, marking a significant capital-raising step that may strengthen its balance sheet and support future growth initiatives.

Biocon Clears Placement Document for Qualified Institutions Share Issue

Biocon Limited has approved and adopted a placement document for a Qualified Institutions Placement (QIP) of equity shares with a face value of ₹5 each, in line with SEBI’s Issue of Capital and Disclosure Requirements Regulations and relevant provisions of the Companies Act, 2013. The move, cleared by the company’s Fund Raising Committee on January 14, 2026, marks a key procedural step toward raising institutional capital, which is expected to strengthen Biocon’s balance sheet and support its strategic growth plans in the competitive biopharmaceuticals market, while signaling continued engagement with institutional investors and public market funding avenues.

Biocon Subsidiary Wins USFDA Nod for Everolimus Oral Suspension Tablets

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg and 5 mg strengths, indicated for the treatment of adult and pediatric patients with Tuberous Sclerosis Complex-related Subependymal Giant Cell Astrocytoma and as adjunctive therapy for TSC-associated partial-onset seizures. The approval adds a specialized central nervous system and oncology-related therapy to Biocon’s U.S. generics portfolio, further strengthening its vertically integrated drug product franchise and supporting its strategy to expand presence in complex, high-value segments of the regulated generics market.

Biocon Sets Record Date for Rs 200 Crore Listed Commercial Paper Maturity

Biocon Limited has announced the record date for the maturity of one of its listed commercial paper issues. The company specified that for its Rs 200 crore commercial paper, bearing ISIN INE376G14057 and maturing on March 3, 2026, the record date has been set as March 2, 2026, with the instrument listed on the National Stock Exchange of India. This disclosure provides clarity to money-market investors and supports transparency in Biocon’s short-term funding arrangements, signaling orderly management of its near-term debt obligations and reinforcing its adherence to listing and compliance norms.

Biocon Lifts Stake in Biocon Biologics to 94% via Share Swap and Cash Deal

Biocon Limited has significantly increased its stake in its unlisted material subsidiary, Biocon Biologics Limited (BBL), through a combination of a large share swap and a partial cash acquisition, consolidating its control to about 94% of BBL’s fully diluted equity capital. In a preferential issue approved by shareholders and stock exchanges, Biocon allotted 171.28 million new equity shares at Rs 405.78 each to existing investors Mylan Inc., Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP as consideration for 261.92 million BBL shares, raising their combined holding in Biocon to 11.36% and expanding Biocon’s paid-up equity capital from Rs 6,684.8 million to Rs 7,541.2 million. Separately, Biocon also completed a cash acquisition of 71.83 million additional BBL shares from Mylan for USD 200 million as part of a larger USD 400 million deal approved earlier, underscoring a strategic move to tighten control over its biologics arm and potentially streamline future value creation and monetisation options for stakeholders.

Biocon Raises Stake in Biocon Biologics to 94% via Share Swap and Cash Deal

Biocon Limited has increased its ownership in its unlisted material subsidiary, Biocon Biologics Limited (BBL), to around 94% of BBL’s fully diluted equity share capital by acquiring a total of 33.38 crore BBL shares. As part of this transaction, Biocon completed a share-swap deal on 5 January 2026, acquiring 26.19 crore BBL shares from Mylan Inc., Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP, and issued 17.13 crore new Biocon shares on a preferential basis to these investors at Rs 405.78 per share, resulting in the allottees collectively holding about 11.36% of Biocon’s expanded equity base. In addition, Biocon paid USD 200 million in cash to Mylan to acquire a further 7.18 crore BBL shares, with the remaining cash leg of the previously approved USD 400 million acquisition to follow. The transaction expands Biocon’s issued share capital and share count, implying equity dilution for existing shareholders but significantly consolidates Biocon’s control over BBL, reinforcing its strategic focus on the biologics segment and potentially enhancing operational and financial integration within the group.

Biocon Shareholders Clear Capital Expansion, Preferential Issue and Higher Investment Limits at EGM

Biocon Limited reported the results of its Extraordinary General Meeting held on 31 December 2025 via video conferencing, where all resolutions on the agenda were approved with the requisite majority. Shareholders voted in favour of increasing the company’s authorised share capital and amending its Memorandum of Association, approving the issuance of equity shares on a preferential basis for consideration other than cash, and raising limits for investments, loans, guarantees, and securities under Section 186 of the Companies Act, 2013. The voting data indicate strong overall support across promoter, institutional and non-institutional categories, although the preferential issue resolution saw a more divided institutional vote before still passing. These approvals collectively provide Biocon additional financial flexibility and capital-raising options, potentially supporting future expansion, strategic investments and balance sheet management, while signalling shareholder backing for the company’s growth and funding plans.